Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma

Biosimilar is an emerging class of medications, that is, similar in safety and efficacy to the original reference product but is a better cost alternative to biologics. In this chapter, we explore the role of biosimilars with special focus on antineoplastic agent Bevacizumab (Avastin) and hepatocellular carcinoma (HCC), which is among the leading causes of cancer-related mortality in the world. Mvasi was the first ever approved biosimilar to Bevacizumab as well as the first biosimilar approved in the United States for the treatment of certain cancers, including colorectal, lung, brain, kidney, and cervical cancers. Increasing attention is being directed toward the development of biosimilars given the economic strain on healthcare systems caused by cancer management and it is imperative that clinicians familiarize themselves with the role of biosimilars. A critical appraisal of the Food and Drug Administration-approved biosimilars, their mechanism(s) of action, indications, usage, and clinical trials with special focus on Bevacizumab and HCC are succinctly covered in this chapter.